ECP
IPXL

Empyrean Capital Partners’s Impax Laboratories, Inc. IPXL Stock Holding History

Empyrean Capital Partners’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-518,821
Closed -$10.5M – 83
2017
Q3 		$10.5M Buy
+518,821
New +$9.92M 0.4% 44

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Empyrean Capital Partners's IPXL Position: Q4 2017 in Review

Empyrean Capital Partners sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 518,821 shares — an estimated $10.5M sold.

Empyrean Capital Partners first reported a position in IPXL in Q3 2017 and held it in 1 quarter. The position peaked at $10.5M in Q3 2017. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

  • Empyrean Capital Partners reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
  • Empyrean Capital Partners sold 518,821 Impax Laboratories, Inc. shares in Q4 2017, an estimated $10.5M.
  • Empyrean Capital Partners first reported a position in Impax Laboratories, Inc. in Q3 2017 and held it in 1 quarter.
  • Empyrean Capital Partners's Impax Laboratories, Inc. position peaked at $10.5M in Q3 2017.
  • 200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Empyrean Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.